Sign In
Buy OTIC
$0.0085
+0 (+0%)
At Close: Jul 11, 2023
Otonomy to Hold Virtual Annual Meeting of Stockholders for 2020
11:30am, Wednesday, 10'th Jun 2020
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that due to the health, safety and travel concerns of stockh
Otonomy to Host Pipeline Program Update Conference Call and Webcast
11:30am, Monday, 08'th Jun 2020
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will host a conference call and webcast to review the sta
Balancing Sars’s powers and duties with taxpayers’ rights and obligations
10:06pm, Sunday, 07'th Jun 2020
In conversation with new tax ombud CEO Thabo Legwaila.
3 “Strong Buy” Biotech Stocks Under $5 With Major Catalysts Approaching
01:56pm, Monday, 01'st Jun 2020
Optimism is on the rise, and investors are wondering if stocks are heading towards recovery territory. So, what does this mean for one industry that has largely outperformed the broader market amid th
Health Check: How Prudently Does Otonomy (NASDAQ:OTIC) Use Debt?
12:32pm, Thursday, 28'th May 2020
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss Program
12:00pm, Tuesday, 12'th May 2020
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical results from the company’s gene therapy collab
Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for ...
12:00am, Tuesday, 12'th May 2020Otonomy Q4 EPS $(0.360) Beats $(0.440) Estimate, Sales $93.000K Beat $50.000K Estimate
12:16pm, Thursday, 07'th May 2020Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate Update
11:30am, Thursday, 07'th May 2020
SAN DIEGO, May 07, 2020 -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported.
Otonomy Reports First Quarter —…—… Financial Results and Provides Corporate Update
12:00am, Thursday, 07'th May 202096 Biggest Movers From Yesterday
08:22am, Tuesday, 28'th Apr 2020
Gainers
Naked Brand Group Limited (NASDAQ: NAKD) shares climbed 60.8% to close at $0.78 on Monday after climbing 8% on Friday.
Yield10 Bioscience, Inc. (NASDAQ: YTEN) shares...
Biohaven on go with study of vazegepant in COVID-19 as others take action amid the pandemic
12:04pm, Thursday, 09'th Apr 2020
The FDA has signed off on a Phase 2 clinical trial evaluating intranasal administration of Biohaven Pharmaceutical Holding Company's (NYSE:BHVN) migraine med vazegepant, a calcitonin gene-related pept
Otonomy Provides Business Update Related to COVID-19 Pandemic
11:30am, Thursday, 09'th Apr 2020
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided a business update related to the COVID-19 pandemic. “Our f
Edited Transcript of OTIC earnings conference call or presentation 27-Feb-20 9:30pm GMT
10:47pm, Thursday, 26'th Mar 2020
Q4 2019 Otonomy Inc Earnings Call
